Xenon Pharmaceuticals Downgraded by Deutsche Bank After Pausing Depression Trial Enrollment
Xenon Pharmaceuticals (NASDAQ: XENE) experienced a significant drop in its stock price, falling nearly 30% to reach levels not seen since November. This decline followed the company's decision to pause enrollment in Phase 3 clinical trials for azetukalner, Xenon’s lead asset for treating depression, due to safety concerns. Deutsche Bank responded by downgrading the stock, citing uncertainty around the drug development timeline and potential regulatory hurdles. Analyst David Hoang highlighted these risks as a key factor behind the downgrade. The move has raised investor concerns about the future of azetukalner's approval prospects and its impact on Xenon’s pipeline. The market reaction underscores how sensitive biotech stocks are to clinical trial setbacks, particularly for companies with limited product portfolios.
Tickers: $XENE